IP Library › Patent Application 14890712
Patent Application
App. No. 14/890,712

VARIANTS OF TNFSF15 AND DCR3 ASSOCIATED WITH CROHN'S DISEASE

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/890,712
Abstract

Described herein are methods and compositions related to the discovery of associations in TNFSF15 15 and DcR3 genetic loci across in Caucasian, Puerto Rican, and Korean Crohn's Disease, as demonstrated via trans-ethnic fine mapping. The present invention provides methods of quantifying risk and diagnosing susceptibility to Crohn's disease in a subject by determining the presence of one or more risk variants are at the TNFSF15 (or TL1A) and/or DcR3 genetic loci.

Claims (26)

1 . An assay for quantifying risk in a subject to Crohn's disease and/or fibrosis, comprising:

obtaining a sample from a subject;

subjecting the sample to a genotyping assay adapted to determine the presence or absence of one or more variants at the TNFSF15 and/or DcR3 genetic loci; and

quantifying risk in a subject to Crohn's disease and/or fibrosis based on the presence of one or more variants at the TNFSF15 and/or DcR3genetic loci.

2 . The method of claim 1 , wherein the variants consist of one or more variants selected from the group consisting of: SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 10, SEQ ID NO. 11, SEQ ID NO. 12, SEQ ID NO. 13, SEQ ID NO. 14, SEQ ID NO. 15, SEQ ID NO. 16, SEQ ID NO. 17, SEQ ID NO. 18, SEQ ID NO. 19, SEQ ID NO. 20, SEQ ID NO. 21, SEQ ID NO. 22, SEQ ID NO. 23, SEQ ID NO. 24, SEQ ID NO. 25, and SEQ ID NO. 26.

3 . The method of claim 1 , wherein the variants are SEQ ID NO. 3 and/or SEQ ID NO.13.

4 . The method of claim 1 , wherein the variant is SEQ ID NO. 22.

5 . The method of claim 1 , wherein the subject is non-Jewish Caucasian, Ashkenazi, South Korean and/or Puerto Rican.

6 . The method of claim 1 , wherein the subject is South Korean and the variant are SEQ ID NO. 3, SEQ ID NO.13 and/or SEQ ID NO. 22.

7 . The method of claim 1 , wherein the variant is a risk variant.

8 . The method of claim 1 , wherein the variant is a protective variant.

9 . The method of claim 1 , wherein the protective variant quantifies a reduced risk in the subject for stricturing, CD, small bowel involvement and/or need for surgical intervention.

10 . A method of diagnosing susceptibility to Crohn's disease and/or fibrosis in a subject, comprising:

obtaining a sample from a subject;

subjecting the sample to a genotyping assay adapted to determine the presence or absence of one or more variants at the TNFSF15 and/or DcR3 genetic loci; and

diagnosing susceptibility to Crohn's disease and/or fibrosis in the subject based on the presence of one or more variants at the TNFSF15 and/or DcR3 genetic loci.

11 . The method of claim 10 , wherein the variants consist of one or more variants selected from the group consisting of: SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 10, SEQ ID NO. 11, SEQ ID NO. 12, SEQ ID NO. 13, SEQ ID NO. 14, SEQ ID NO. 15, SEQ ID NO. 16, SEQ ID NO. 17, SEQ ID NO. 18, SEQ ID NO. 19, SEQ ID NO. 20, SEQ ID NO. 21, SEQ ID NO. 22, SEQ ID NO. 23, SEQ ID NO. 24, SEQ ID NO. 25, and SEQ ID NO. 26.

12 . The method of claim 10 , wherein the variants are SEQ ID NO. 3 and/or SEQ ID NO.13.

13 . The method of claim 10 , wherein the variant is SEQ ID NO. 22.

14 . The method of claim 10 , wherein the subject is non-Jewish Caucasian, Ashkenazi, South Korean and/or Puerto Rican.

15 . The method of claim 10 , wherein the subject is South Korean and the variant are SEQ ID NO. 3, SEQ ID NO.13 and/or SEQ ID NO. 22.

16 . A method of treating Crohn's disease and/or fibrosis in a subject, comprising:

obtaining a sample from the subject;

subjecting the sample to a genotyping assay adapted to determine the presence of one or more variants at the TNFSF15 and/or DcR3 genetic loci; and

treating the Crohn's disease and/or fibrosis.

17 . The method of claim 16 , wherein the variants consist of one or more variants selected from the group consisting of: SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 10, SEQ ID NO. 11, SEQ ID NO. 12, SEQ ID NO. 13, SEQ ID NO. 14, SEQ ID NO. 15, SEQ ID NO. 16, SEQ ID NO. 17, SEQ ID NO. 18, SEQ ID NO. 19, SEQ ID NO. 20, SEQ ID NO. 21, SEQ ID NO. 22, SEQ ID NO. 23, SEQ ID NO. 24, SEQ ID NO. 25, and SEQ ID NO. 26.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2015
From: MCGOVERN, DERMOT P.
To: CEDARS-SINAI MEDICAL CENTER
Reel/Frame 037034/0176 →